NEWTOWN, Pa., Nov. 17, 2021 /PRNewswire/
-- Clinical trials are a key step to bringing new
pharmaceutical drugs to market, but they are also faced with an
increasing number of challenges, from recruitment challenges to
missed enrollment targets and patient dropouts. Accordingly, the
pharmaceutical industry is quickly pivoting away from
"site-centric" to "patient-centric" clinical trials. EPAM
Systems, Inc. (NYSE: EPAM), a leading digital
transformation services and product engineering company, announced
today the launch of their new Digital Clinical Trials (DCT)
platform. Powered by Microsoft cloud services, the
solution is a digital, patient-centric platform that connects
patients, Clinical Research Organizations (CRO), and healthcare
provider teams to deliver the future of hybrid or decentralized
clinical trials through a virtual, effortless, outcome-driven
experience—making them more accessible, affordable, and faster.
CLOUD-BASED, MODULAR, INTEGRATED.
- Recruit Patients at Home with Digital Enrollment.
Utilize remote screening at scale. Meet study enrollment targets
faster and develop screening assessments to suit study needs and
patient preferences.
- Clinical Trial Roadmap. Patients have an on-demand view
into their personalized clinical trial experience at each step
while they prepare for and manage their health.
- Omnichannel Communication. Bring secure, convenient, and
reliable communication channels to patients wherever they are via
telehealth, mobile messaging and/or eChat bots.
- Increase Compliance. Simple to use, connected devices
that enable real-time patient outcome updates through
integration.
- Connected Apps Drive Efficiency and Reduce Study
Timelines. Accelerate study start-up timelines by facilitating
easy document exchange between sponsor teams and trial site
teams
"We're pleased to partner with Microsoft cloud services to bring
the Digital Clinical Trials platform to market," said Sergey
Yezhkov, SVP and Co-Head Global Business, EPAM Systems. "DCT gives
pharmaceutical organizations access to real-time data via secure
omnichannel communication channels, while simultaneously
simplifying the patient recruitment and enrollment process,
enabling seamless integration of patient outcomes, improving
operational efficiencies, reducing study timelines, and increasing
patient engagement."
"Clinical trials are an important element in bringing new drugs
to market," said Daniel Carchedi,
Sr. Director of Business Development & Strategy at Microsoft.
"Together with EPAM, we are working to help our customers transform
their businesses, and we're delivering impactful, human-centered
solutions to the market every day."
Learn more about EPAM's new Cloud-Powered Digital Clinical
Trials Platform at epam.com/DCT.
About EPAM Systems
Since 1993, EPAM Systems, Inc.
(NYSE: EPAM) has leveraged its advanced software engineering
heritage to become the foremost global digital transformation
services provider – leading the industry in digital and physical
product development and digital platform engineering services.
Through its innovative strategy; integrated advisory, consulting
and design capabilities; and unique 'Engineering DNA,' EPAM's
globally deployed hybrid teams help make the future real for
clients and communities around the world by powering better
enterprise, education and health platforms that connect people,
optimize experiences, and improve people's lives. Selected by
Newsweek as a 2021 Most Loved Workplace, EPAM's global
multi-disciplinary teams serve customers in more than 40 countries
across five continents. As a recognized leader, EPAM is listed
among the top 15 companies in Information Technology Services on
the Fortune 1000 and ranked as the top IT services company on
Fortune's 100 Fastest-Growing Companies list for the last three
consecutive years. EPAM is also listed among Ad Age's top 25
World's Largest Agency Companies and in 2020, Consulting Magazine
named EPAM Continuum a top 20 Fastest-Growing Firm. Learn more at
http://www.epam.com and follow EPAM on Twitter and
LinkedIn.
Forward-Looking Statements
This press release
includes statements which may constitute forward-looking statements
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, the accuracy of which are
necessarily subject to risks, uncertainties, and assumptions as to
future events that may not prove to be accurate. Factors that could
cause actual results to differ materially from those expressed or
implied include general economic conditions and the factors
discussed in our most recent Annual Report on Form 10-K and other
filings with the Securities and Exchange Commission. EPAM
undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, except as may be required under applicable securities
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/epam-debuts-new-cloud-powered-digital-clinical-trials-platform-301426393.html
SOURCE EPAM Systems, Inc.